In mutant KRAS-expressing NSCLC, KRAS increases SREBP1 expression in part by MEK1/2 signaling and SREBP-1 knockdown significantly inhibits cell proliferation through regulating mitochondrial metabolism (107). Here, SREBF1 is linked to non-small cell lung carcinoma.